The liver and lovastatin

American Journal of Cardiology

Volumn 89, Issue 12, 2002, Pages 1374-1380

  Tolman, Keith G ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ANTILIPEMIC AGENT; CAPTOPRIL; COLESTYRAMINE; CYTOCHROME P450 INHIBITOR; ERYTHROMYCIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PROBUCOL;

ACUTE HEPATITIS; ARTICLE; CHOLESTATIC HEPATITIS; CHOLESTEROL BLOOD LEVEL; CHRONIC ACTIVE HEPATITIS; CLINICAL TRIAL; DIAGNOSTIC VALUE; DOSE RESPONSE; DRUG APPROVAL; DRUG METABOLISM; ENZYME BLOOD LEVEL; FATTY LIVER; HUMAN; HYPERCHOLESTEROLEMIA; JAUNDICE; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FAILURE; LIVER FUNCTION TEST; LIVER NECROSIS; LIVER TOXICITY; NONHUMAN; POSTMARKETING SURVEILLANCE; PREDICTION; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; RISK FACTOR;

ANIMALS; ANTICHOLESTEREMIC AGENTS; CLINICAL TRIALS; HUMANS; LIVER; LIVER DISEASES; LIVER FUNCTION TESTS; LOVASTATIN; PRODUCT SURVEILLANCE, POSTMARKETING; RISK FACTORS;

EID: 0037097465     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(02)02355-X     Document Type: Article

References (29)

1. Competitive inhibition of 3-hydroxy-3-methylglutanyl coenzyme A reductase by ML-236A and ML-236B, fungal metabolites having hypocholesterolemic activity
2. Preclinical evaluation of lovastatin
3. Toxicity of the HMG-CoA reductase inhibitor, lovastatin, to rabbits
4. Biochemical charges and morphological alterations of the liver in guinea pigs after administration of simvastatin HMG-CoA reductase-inhibitor
5. Expanded clinical evaluation of lovastatin (EXCEL) study results: IV additional perspectives on the tolerability of lovastatin
6. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS
7. Acute liver failure
8. Fulminant hepatic failure: Summary of a workshop
9. Hepatitis due to lovastatin
10. Hepatitis associated with treatment with lovastatin. Presentation of 2 cases
11. Non-alcohol steatohepatitis
12. Descriptive epidemiology of acute liver enzyme abnormalities in the general population of central Massachusetts
13. Lovastatin - Acetaminophen subchronic toxicity in mice
14. Multiple organ toxicity from addition of erythromycin to long-term lovastatin therapy
15. Drug-induced hepatitis associated with anticytoplasmic organelle autoantibodies
16. Acute cholestatic hepatitis during simvastatin administration
17. Acute cholestatic hepatitis associated with pravastatin
18. Clofibrate hepatitis, a case report
19. Hepatitis after germander (teucrium chamaedrys) administration: Another instance of herbal medicine hepatotoxicity
20. A comparison of the efficacy and toxic effects of sustained vs immediate-release niacin in hypercholesterolemic patients
21. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian simvastatin survival study
22. Randomized trial of cho-lesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4b)
23. Effect on hepatic morphology of treatment of obesity by fasting, reducing diets and small bowel bypass
24. Safety of nonsteroidal anti-inflammatory drugs with respect to acute liver disease
25. Outpatient drug-induced parenchymal liver disease requiring hospitalization
26. Jaundice after repeated exposure to halothane: An analysis of reports to the Committee on Safety of Medicine
27. The erythromycins: A further report from the Australian Drug Evaluation Committee